TSE:MFC

Manulife Financial (MFC.TO)

57.04
+0.49 (0.87%)
as of Jun 25, 2026, 8:00:00 pm Market Open.
1634 watching
0
Investor Insights
star iconJun 25, 2026, 12:00 am

This summary was created by AI, based on 28 opinions in the last 12 months.

Experts hold a mixed view on Manulife Financial (MFC), reflecting both cautious optimism and concerns over its growth prospects. Many analysts recognize the company's strong performance in Asian markets and wealth management, noting its potential for steady income through dividends, with several projecting double-digit growth. However, there are reservations regarding the current valuation, with some analysts suggesting a wait for market pullbacks before purchasing. Despite recent underperformance relative to peers and profit-taking activities, MFC is still viewed as a reliable long-term investment, especially for dividend-seeking investors. Concerns about broader market conditions and legacy business challenges persist, but the company's fundamentals appear solid.

consensus icon
Consensus
Hold
valuation icon
Valuation
Fair Value
review icon
Similar
SLF
BUY
Trevor Rose’s Insights - Trevor’s most-liked answers from 5i Research

MFC is now trading at 7.3x times the forward P/E. In the 3Q, MFC’s core EPS grew 35% to $0.92, beating estimates of $0.81. Core ROE is also quite healthy around 16.8%. The adjusted book value per share grew 4% to $30.67. The balance sheet is healthy, with long-term debt of $13B and long-term debt/equity stands at 0.21x. Overall, a solid quarter for MFC MFC has also ramped up share buybacks in recent quarters, which we like. One of the reasons we like SLF over MFC is due to its  track record. SLF is more conservative in the way they run their business. For example, SLF did not have to cut its dividend in the financial crisis of 2008, while MFC did. It has, simply, proven more reliable over the past two decades. It is a bit more expensive, but we think the premium is justified. 
Unlock Premium - Try 5i Free

HOLD

We're getting closer to a Buy signal for Canadian banks, a lot of fear is already priced in. He'd be looking to pick up some banks, given they're trading at a rarely seen below 10x. MFC and the like have held in fairly well, so he'd be looking to buy banks over insurance at this point.

DON'T BUY

It's cheap and pays a decent dividend. The problem is no growth. North America is mature, but Asia is limited for them. Is only modest growth in earnings. He doesn't know if things get better in the short term.

premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
(A Top Pick Sep 26/23, Down 4.4%)Stockchase Research Editor: Michael O'Reilly

Our PAST TOP PICK with MFC has triggered its stop at $24.  To remain disciplined, we recommend covering the position at this time.  This will result in a net investment loss of 3%, when combined with our previous recommendations.  

HOLD

Share price volatility frustrating. Not building value in shares over the long run. Would recommend holding shares. ~5% yield in shares attractive. Owns shares in company. 

SELL ON STRENGTH

Doesn't own any lifecos, prefers P&C and banks. Dogged by US business divisions, trying to divest. Canadian business is a modest grower. Star is the Asian business, which is 1/3 of operations. Always trades in single digits, 5+% yield, never seems to get above $30. He's neutral. Sell if it gets to $30.

premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK
Stockchase Research Editor: Michael O'Reilly

As quarterly cash reserves grow while debt is retired and shares bought back, we reiterate MFC as a TOP PICK. It pays a good dividend that has grown annually by 10% a year over the past decade.  It trades at 7x earnings, 1.2x book and supports a robust 25% ROE.  We continue to recommend a stop at $24, looking to achieve $29 -- upside potential of 14%.  Yield 5.4% 

(Analysts’ price target is $29.31)
DON'T BUY

Very complicated business model.
Difficult to determine long term prospects of business.
Higher interest rates usually good for insurance, but not panning out.
Better names within sector to invest in.

SELL

Has owned in the past, but since sold shares.
Earnings growth not very good.
Valuation attractive, but not worthwhile.
Investment income in alternative assets not living up to expectations.
Exposure to Hong Kong also not living up to expectations. 

HOLD

Market sensitive stock due to asset management business.
10 year performance not very good.
Owns shares due to dividend only.
Not expecting major capital appreciation.
Long term investment (10-15 years). 

PAST TOP PICK
(A Top Pick Jul 28/22, Up 16%)

A glass half full type of stock, it's not perfect. Issues with long-duration assets right now. All this is built into the story, nothing has changed with his thesis. 7.3x 2024 earnings, 11% compelling growth rate.

COMMENT

It is the largest life insurance company in Canada and is strong in Asia where there is high growth. It has traded sideways recently as well as long term. Its dividend is over 6%. They sold their shares and rotated into another life insurance company

COMMENT

High quality. Arguably more upside than others, with its greater exposure to Asia.

TRADE

Owns it for income. MFC has a wall of $27; the stock never breaches that. It's in technical prison. It goes up and down like a toilet seat. Collect the dividend.

DON'T BUY

A perennial trader between $20-30. Buy at the low end at sell at the high end if you're an active trader. Otherwise, it doesn't compare well vs. the banks or P&C insurers. Their legacy US business holds them back.

Showing 106 to 120 of 2,281 entries